论文部分内容阅读
探讨艾塞那肽(Exenatide)与预混胰岛素治疗2型糖尿病的临床疗效对照。选取2型糖尿病患者,随机分为艾塞那肽组与预混胰岛素组各28例,均治疗4个月,比较两组各项指标。两组治疗前后进行比较,患者空腹血糖(FPG),2 h餐后血糖(2 h PG),糖化血红蛋白(Hb Alc)均明显降低。艾塞那肽组治疗后稳态模型指数HOMA-IR,和体重指数(BMI)显著下降,生化指标总胆固醇(TC),低密度脂蛋白(LDL-C),谷氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)显著下降,临床不良反应轻微。艾塞那肽治疗2型糖尿病患者,可以良好的控制血糖,减轻体重,改善胰岛素抵抗和脂质代谢紊乱。相对预混胰岛素而言,艾塞那肽能更有效地降低患者体重指数,降低糖化血红蛋白和低血糖发生率,值得临床应用。
To investigate the clinical efficacy of exenatide and premixed insulin in the treatment of type 2 diabetes. Patients with type 2 diabetes mellitus were randomized into exenatide group and premixed insulin group, 28 cases each for 4 months. The indexes of both groups were compared. The levels of fasting blood glucose (FPG), 2-h postprandial blood glucose (2 h PG), and HbAc were significantly lower in both groups before and after treatment. The steady state model index (HOMA-IR) and body mass index (BMI) decreased significantly in the exenatide group after treatment. The biochemical indicators of total cholesterol (TC), low density lipoprotein (LDL-C), glutamate aminotransferase ) And aspartate aminotransferase (AST) decreased significantly, clinical adverse reactions minor. Exenatide in patients with type 2 diabetes, can control blood sugar, reduce weight, improve insulin resistance and lipid metabolism disorders. Compared with premixed insulin, exenatide is more effective in reducing the patient’s body mass index, reducing the incidence of HbAlc and hypoglycemia, worthy of clinical application.